Tech Company Financing Transactions

Epizyme Funding Round

Amgen Ventures, Bay City Capital and Kleiner Perkins Caufield & Byers participated in a $32 million Series B venture round for Epizyme. The round was recorded on 10/7/2009.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B

Amgen Ventures

Bay City Capital (Carl Goldfischer)

Kleiner Perkins Caufield & Byers (Beth Seidenberg)

MPM Capital (Kazumi Shiosaki)

Proceeds Purpose
Rapid progress has been made at Epizyme in evolving a robust pipeline of first-in-class inhibitors of histone methyltransferase (HMT) enzymes involved in cancer," said Epizyme chief executive officer Kazumi Shiosaki, PhD. "With the support of our new investors as well as our existing investors, we are now in a position to progress a number of these lead programs into proof-of-concept studies.

Company Information

Company Status
Mailing Address
400 Technology Sq. 4th Floor
Cambridge, MA 02139
Email Address
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company?s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs).
Epizyme LinkedIn Company Profile
Social Media
Epizyme Company Twitter Account
Company News
Epizyme News
Epizyme on Facebook
Epizyme on YouTube

Management Team

Email & Social
Chief Executive Officer
Robert Bazemore
  Robert Bazemore LinkedIn Profile  Robert Bazemore Twitter Account  Robert Bazemore News  Robert Bazemore on Facebook
Chief Financial Officer
Paolo Tombesi
  Paolo Tombesi LinkedIn Profile  Paolo Tombesi Twitter Account  Paolo Tombesi News  Paolo Tombesi on Facebook
Chief Medical Officer
Shefali Agarwal
  Shefali Agarwal LinkedIn Profile  Shefali Agarwal Twitter Account  Shefali Agarwal News  Shefali Agarwal on Facebook
Chief Operating Officer
Matthew Ros
  Matthew Ros LinkedIn Profile  Matthew Ros Twitter Account  Matthew Ros News  Matthew Ros on Facebook
VP - General Counsel
John Weidenbruch
  John Weidenbruch LinkedIn Profile  John Weidenbruch Twitter Account  John Weidenbruch News  John Weidenbruch on Facebook
VP - Regulatory Affairs
Mark De Rosch
  Mark De Rosch LinkedIn Profile  Mark De Rosch Twitter Account  Mark De Rosch News  Mark De Rosch on Facebook



Browse more venture capital transactions:

Prev: 10/7/2009: Daptiv venture capital transaction
Next: 10/7/2009: Engine Yard venture capital transaction


Share this article


About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary